CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs
- PMID: 20847137
- DOI: 10.1124/dmd.110.034140
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs
Abstract
CYP3A4, the major form of cytochrome P450 (P450) expressed in the adult human liver, is involved in the metabolism of approximately 50% of commonly prescribed drugs. Several genetic polymorphisms in CYP3A4 are known to affect its catalytic activity and to contribute in part to interindividual differences in the pharmacokinetics and pharmacodynamics of CYP3A4 substrate drugs. In this study, catalytic activities of the two alleles found in East Asians, CYP3A4*16 (T185S) and CYP3A4*18 (L293P), were assessed using the following seven substrates: midazolam, carbamazepine, atorvastatin, paclitaxel, docetaxel, irinotecan, and terfenadine. The holoprotein levels of CYP3A4.16 and CYP3A4.18 were significantly higher and lower, respectively, than that of CYP3A4.1 when expressed in Sf21 insect cell microsomes together with human NADPH-P450 reductase. CYP3A4.16 exhibited intrinsic clearances (V(max)/K(m)) that were lowered considerably (by 84-60%) for metabolism of midazolam, carbamazepine, atorvastatin, paclitaxel, and irinotecan compared with CYP3A4.1 due to increased K(m) with or without decreased V(max) values, whereas no apparent decrease in intrinsic clearance was observed for docetaxel. On the other hand, K(m) values for CYP3A4.18 were comparable to those for CYP3A4.1 for all substrates except terfenadine; but V(max) values were lower for midazolam, paclitaxel, docetaxel, and irinotecan, resulting in partially reduced intrinsic clearance values (by 34-52%). These results demonstrated that the impacts of both alleles on CYP3A4 catalytic activities depend on the substrates used. Thus, to evaluate the influences of both alleles on the pharmacokinetics of CYP3A4-metabolized drugs and their drug-drug interactions, substrate drug-dependent characteristics should be considered for each drug.
Similar articles
-
Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.Xenobiotica. 2009 Feb;39(2):140-7. doi: 10.1080/00498250802617746. Xenobiotica. 2009. PMID: 19255940
-
Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.Drug Metab Dispos. 2008 Nov;36(11):2287-91. doi: 10.1124/dmd.108.021816. Epub 2008 Jul 31. Drug Metab Dispos. 2008. PMID: 18669585
-
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Drug Metab Dispos. 2003 Jan;31(1):53-9. doi: 10.1124/dmd.31.1.53. Drug Metab Dispos. 2003. PMID: 12485953
-
Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.Cancer Treat Rev. 2013 Nov;39(7):773-83. doi: 10.1016/j.ctrv.2012.12.008. Epub 2013 Feb 8. Cancer Treat Rev. 2013. PMID: 23394826 Review.
-
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.Clin Pharmacokinet. 2005;44(3):279-304. doi: 10.2165/00003088-200544030-00005. Clin Pharmacokinet. 2005. PMID: 15762770 Review.
Cited by
-
Dechlorination and demethylation of ochratoxin A enhance blocking activity of PXR activation, suppress PXR expression and reduce cytotoxicity.Toxicol Lett. 2020 Oct 10;332:171-180. doi: 10.1016/j.toxlet.2020.07.012. Epub 2020 Jul 10. Toxicol Lett. 2020. PMID: 32659470 Free PMC article.
-
Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?Eur J Med Res. 2023 Sep 27;28(1):381. doi: 10.1186/s40001-023-01038-1. Eur J Med Res. 2023. PMID: 37759317 Free PMC article. Review.
-
PharmGKB summary: carbamazepine pathway.Pharmacogenet Genomics. 2011 Dec;21(12):906-10. doi: 10.1097/FPC.0b013e328348c6f2. Pharmacogenet Genomics. 2011. PMID: 21738081 Free PMC article. No abstract available.
-
Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms.CNS Neurol Disord Drug Targets. 2024;23(12):1463-1473. doi: 10.2174/0118715273298953240529100325. CNS Neurol Disord Drug Targets. 2024. PMID: 38859787
-
Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.G3 (Bethesda). 2013 Jan;3(1):91-9. doi: 10.1534/g3.112.003996. Epub 2013 Jan 1. G3 (Bethesda). 2013. PMID: 23316441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources